MORRISVILLE, N.C., July 25, 2011 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) and privately held Aurum Biosciences, Ltd. of Glasgow, Scotland, today announced they signed a Letter of Intent (LOI) to conduct preclinical research for imaging and therapeutic intervention of acute ischemic stroke. The research will be conducted by Aurum using Oxygen’s proprietary Oxycyte® PFC (perfluorocarbon) emulsion in combination with Aurum’s proprietary Glasgow Oxygen Level Dependent (GOLD) Magnetic Resonance Imaging techniques.
